In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related